Business
InMed Pharmaceuticals Announces NSERC Grant to The University of British Columbia in Support of Collaborative R&D Work
InMed Pharmaceuticals Announces NSERC Grant to The University of British Columbia in Suppo...
About this update from Infield Minerals Corp
[{"type":"text","content":"\n\n\n\nInMed Pharmaceuticals Announces NSERC Grant to The University of British Columbia in Support of Collaborative R&D Work\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nInMed Pharmaceuticals Announces NSERC Grant to The University of British Columbia in Support of Collaborative R&D Work\nCanada NewsWire\nVANCOUVER, Sept. 11, 2018\n\n\n\nVANCOUVER, Sept. 11, 2018 /CNW/ - InMed Pharmaceuticals Inc. (\"InMed\" or the \"Company\") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary biosynthesis platform technology to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today announced that the Company's research partner, University of British Columbia (\"UBC\"), has been approved to receive a grant from the Natural Sciences and Engineering Research Council of Canada (\"NSERC\") for their collaborative efforts with InMed in the biosynthesis of cannabinoids (the \"Collaboration\").\n\n\n \n \n\n \nUnder the terms of the grant, the NSERC has committed funding of C$136,000 towards the Collaboration over the course of three years.  The Collaboration, entitled 'Microbial metabolic engineering for cannabinoid biosynthesis', which originally commenced in May 2015, targets development of a microbial-based cannabinoid expression system for the manufacture of individual cannabinoid drugs for treating diseases with high unmet medical needs.\n\nInMed's Vice President, Pre-Clinical Research & Development, Eric Hsu, Ph.D., commented, \"We are honored that our trusted, world-class research partner, Dr. Yadav at UBC, has received this prestigious grant from the NSERC.  Through our continued research effort on this program with UBC, we remain optimistic that the development of our proprietary biosynthesis platform technology will result in commercial-scale manufacturing of cannabinoids.\"\n\n\"We would like to take this opportunity to extend our gratitude to the NSERC for their vote of confidence in our cutting-edge work,\" added Vikramaditya G. Yadav, Ph.D., A...